Previous 10 | Next 10 |
Compugen Ltd. (NASDAQ:CGEN) Q4 2020 Earnings Conference Call February 25, 2021, 8:30 AM ET Company Participants Elana Holzman - Director, IR and Corporate Communications Anat Cohen-Dayag - President and CEO Henry Adewoye - SVP and CMO Ari Krashin - CFO and COO Eran Ophir - VP, Research and Dr...
Compugen Reports Fourth Quarter and Full Year 2020 Results Encouraging signals of anti-tumor activity demonstrated across COM701 Phase 1 combination and monotherapy studies with durable responses, including a complete response, in tumor types typically unresponsive to checkpoint...
Compugen Announces Data Update from COM701 Phase 1 Clinical Trial Durable responses observed with COM701 in combination with Opdivo® including a confirmed complete response in a patient with prior progression on Opdivo® COM701 monotherapy demonstrates signals of an...
Compugen (NASDAQ:CGEN) is scheduled to announce Q4 earnings results on Thursday, February 25th, before market open.The consensus EPS Estimate is -$0.10Over the last 1 year, CGEN has beaten EPS estimates 50% of the time and has beaten revenue estimates 25% of the time. For further details se...
Compugen ([[CGEN]] -5.3%) announces the expansion of its clinical collaboration agreement with Bristol Myers Squibb ([[BMY]] -0.1%) to supply blockbuster cancer treatment Opdivo (nivolumab), for Compugen's Phase 1b cohort expansion study to assess COM701, an anti-PVRIG antibody, in...
Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo® Cohort expansion study expected to commence in the second quarter of 2021 PR Newswire HOLON, Israel , Feb. 22, 2021 /PRNews...
Compugen to Release Fourth Quarter and Full Year 2020 Results on Thursday, February 25, 2021 PR Newswire HOLON, Israel , Feb. 16, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predict...
Familiar names topped ARK Investment Management's actively-managed ETFs last quarter, while work-from-home stocks pulled down performance as enthusiasm for recovery stocks arrived with vaccine approvals.And in her note about Q4 performance, ARK CEO Cathie Wood said it looks like cyclical sect...
Compugen (CGEN) announces progress from its ongoing license agreement with AstraZeneca (AZN).Under the terms of the agreement, Compugen provided an exclusive license for the development of bispecific and multi-specific antibody products, with AstraZeneca responsible for all research, dev...
Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products PR Newswire HOLON, Israel , Dec. 23, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clini...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...